News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Block & Leviton LLP Investigates ISTA Pharmaceuticals, Inc. (ISTA)'s Board of Directors for Possible Breaches of Fiduciary Duty


3/27/2012 6:53:02 AM

BOSTON, March 26, 2012 /PRNewswire/ -- Block & Leviton LLP (www.blockesq.com), a Boston-based law firm representing investors nationwide, has commenced an investigation into possible breaches of fiduciary duties by the Board of Directors of ISTA Pharmaceuticals, Inc. ("ISTA" or the "Company") (NASDAQ: ISTA) concerning the proposed acquisition of the Company by Bausch & Lomb for $9.10 per share in cash, or approximately $500 million.

Block & Leviton's investigation seeks to determine, among other things, whether ISTA's Directors breached their fiduciary duties by failing to maximize shareholder value in the proposed transaction. Bausch & Lomb's offer is a mere 10% premium to the Company's share price on March 23, 2012, the last trading day before the merger was announced.

If you have any information relevant to this investigation, or have questions about your legal rights, please contact Mark Alan Delaney of Block & Leviton LLP at (617) 398-5650 or email him at Mark@blockesq.com.

Block & Leviton is a Boston-based law firm representing investors for violations of securities laws. The firm's lawyers have collectively been prosecuting securities cases on behalf of investors for over 50 years.

This notice may constitute attorney advertising.

Contact:

BLOCK & LEVITON LLP

Mark A. Delaney, Esq.

(617) 398-5650

Mark@blockesq.com

Jason M. Leviton, Esq.

(617) 398-5620

Jason@blockesq.com

SOURCE Block & Leviton LLP


Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES